Daewoong Pharmaceutical and DNC Aesthetics Host Engaging Symposium
Daewoong Pharmaceutical and DNC Aesthetics Host Engaging Symposium
  • Kim Min-jee
  • 승인 2025.06.02 12:01
  • 댓글 0
이 기사를 공유합니다

Daewoong Pharmaceutical and DNC Aesthetics are hosting the DEEP Symposium event, where lectures are being conducted. / Courtesy of Daewoong Pharmaceutical

Daewoong Pharmaceutical and DNC Aesthetics garnered significant attention from medical professionals by hosting a hands-on symposium focused on tailored aesthetic solutions for individuals in their 40s. 

The two companies held the "DEEP (Daewoong·DNC Medical-AEsthetic Expert Program) Symposium" from May 31 to June 1 at the JW Marriott Hotel in Seoul, highlighting treatment strategies suitable for addressing the skin aging concerns that become prominent in the 40s.

A key feature of the event was its interactive format. Attendees engaged in discussions about actual treatment plans with presenters and experienced the procedures in real-time through dual live broadcasts, enhancing the event's realism. During this session, detailed clinical data on how Daewoong Pharmaceutical’s key aesthetic products are combined and applied was shared.

The main programs covered anti-aging treatment strategies using Botulinum toxin ‘Nabota,’ fat-dissolving injection ‘Violet,’ and filler ‘Decla,’ as well as facial contour improvement techniques using lifting threads. Theoretical knowledge and practical demonstrations were integrated throughout.

Dr. Lee Jong-hoon from Leejebel Clinic noted, “The 40s require comprehensive management due to simultaneous volume loss and elasticity decline. Step-by-step personalized treatments using Daewoong’s products are effective in maintaining a natural and youthful appearance.”

Dr. Jang Du-yeol from Change Clinic added, “The 40s are a period needing diverse approaches rather than single treatments. 'Decla' and 'Duse' are ideally suited for complex treatment strategies.”

Yoon Joon-soo, head of Daewoong Pharmaceutical’s Nabota business division, stated, “This symposium, where medical professionals shared practical solutions, marks an important starting point for future treatment trends.”

Meanwhile, Daewoong Pharmaceutical is accelerating its efforts to expand in the global market, leveraging its aesthetic portfolio, including the FDA-approved Botulinum toxin ‘Nabota,’ Korea's first fat-dissolving injection ‘Violet,’ filler ‘Decla,’ and suture ‘Duse.’


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.

  • ABOUT
  • CONTACT US
  • SIGN UP MEMBERSHIP
  • RSS
  • URL : www.koreaittimes.com | Tel : +82-2-578- 0434 / + 82-10-2442-9446 | North America Dept: 070-7008-0005
  • Email : info@koreaittimes.com | Publisher. Editor :: Chung Younsoo
  • Masthead: Korea IT Times. Copyright(C) Korea IT Times, All rights reserved.
ND소프트